A Hims & Hers Health apresentou uma receita abaixo do esperado no primeiro trimestre em meio a pressões nas margens.
A empresa está se afastando de medicamentos GLP-1 manipulados em direção a parcerias de marca com a Novo Nordisk e a Eli Lilly. Espera-se que essa mudança afete as margens no curto prazo, ao mesmo tempo em que reduz os riscos legais associados à manipulação de fórmulas.
Sun Pharmaceutical Industries posted robust revenue and profit increases for the March quarter. The company noted pressure on EBITDA margins due to higher investments and reduced milestone income. Outlook for the next fiscal year points to steady but moderated expansion.
Reportado por IA
ARS Pharmaceuticals held its first quarter 2026 earnings conference call on May 15, highlighting early momentum in the new year. Company executives emphasized growth drivers including expanded access for its neffy product. The call featured forward-looking statements about the firm's commercial progress.
L’Oréal Group posted a 7.6% like-for-like revenue increase to €12.2 billion in the first quarter of fiscal 2026, exceeding analyst expectations. The results marked an acceleration from the previous quarter. CEO Nicolas Hieronimus credited innovation and e-commerce strength for global market share gains.
Reportado por IA
Brandon Sim, president and chief executive of Astrana Health, discussed the company's recent performance during a presentation at the Bank of America Global Healthcare Conference on May 12. He highlighted rapid growth and positive first-quarter outcomes. The value-based care provider continues to expand while maintaining profitability.